AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32200854 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 32201256 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning algorithms (support vector machines, random forests, gradient boosting machines, artificial neural networks)
Number of subjects: 11022
Study 32201256 — intervention group
Group type: COMPARATOR
Intervention: Logistic regression, lasso regression, ridge regression
Number of subjects: 11022
Study 32201274 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-lowering treatment
Number of subjects: 2648
Study 32201506 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib (200 mg orally twice daily, days 1-5 and 8-12) and Bevacizumab (5 mg/kg intravenously, day 1) every 2 weeks
Number of subjects: 79
Study 32201505 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-06649751
Number of subjects: 57
Study 32201505 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 32202224 — intervention group
Group type: EXPERIMENTAL
Intervention: Caspofungin
Number of subjects: 20
Study 32202706 — intervention group
Group type: EXPERIMENTAL
Intervention: Total daily sitting
Number of subjects: 380
Study 32202706 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational sitting
Number of subjects: 380
Study 32202706 — intervention group
Group type: EXPERIMENTAL
Intervention: Television viewing
Number of subjects: 380
Study 32202706 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer use
Number of subjects: 380
Study 32202706 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily sedentary time (accelerometer subsample)
Number of subjects: 380
Study 32203069 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin 80 mg daily for 4-12 weeks
Number of subjects: 33
Study 32203069 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin 80 mg daily for >50 days
Number of subjects: 33
Study 32203155 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium treatment
Number of subjects: 2586
Study 32203233 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-dimensional optical imaging (3DO)
Number of subjects: 179
Study 32203233 — intervention group
Group type: COMPARATOR
Intervention: 4-component (4C) model
Number of subjects: 179
Study 32203268 — intervention group
Group type: EXPERIMENTAL
Intervention: Treosulfan-based conditioning treatment
Number of subjects: 65
Study 32203306 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma circulating tumour DNA (ctDNA) analysis
Number of subjects: 0
Study 32203306 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma ctDNA testing
Number of subjects: 0
Study 32203698 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemigatinib 13.5 mg orally once daily (21-day cycle; 2 weeks on, 1 week off)
Number of subjects: 146
Study 32203698 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemigatinib
Number of subjects: 146
Study 32204733 — intervention group
Group type: EXPERIMENTAL
Intervention: melphalan hypoxic pelvic perfusion (HPP)
Number of subjects: 7
Study 32205016 — intervention group
Group type: EXPERIMENTAL
Intervention: Capivasertib (AZD5363) 320 mg, 400 mg, and 480 mg twice daily (b.i.d.) for 4 days on and 3 days off in combination with enzalutamide 160 mg daily
Number of subjects: 16
Study 32205016 — intervention group
Group type: EXPERIMENTAL
Intervention: Capivasertib (AZD5363) 400 mg b.i.d. with enzalutamide 160 mg daily
Number of subjects: 16
Study 32205017 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipatasertib 600 mg combined with paclitaxel
Number of subjects: 122
Study 32205017 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipatasertib 600 mg combined with mFOLFOX6
Number of subjects: 122
Study 32205017 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipatasertib 400 mg combined with paclitaxel
Number of subjects: 122
Study 32205017 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipatasertib combined with docetaxel
Number of subjects: 122
Study 32205017 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipatasertib combined with enzalutamide
Number of subjects: 122
Study 32205017 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipatasertib combined with chemotherapy or hormonal therapy
Number of subjects: 122
Study 32205068 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonfasting
Number of subjects: 15397
Study 32205112 — intervention group
Group type: EXPERIMENTAL
Intervention: TEVAR with JOTEC E-XL open stent
Number of subjects: 39
Study 32205112 — intervention group
Group type: COMPARATOR
Intervention: TEVAR alone
Number of subjects: 39
Study 32205128 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovenous laser therapy using a 400-μm optical fiber with a 1470-nm laser
Number of subjects: 0
Study 32205218 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-based deep convolutional neural network (CNN) analysis
Number of subjects: 950
Study 32205218 — intervention group
Group type: EXPERIMENTAL
Intervention: MR-based deep convolutional neural network (CNN) analysis
Number of subjects: 950
Study 32205328 — intervention group
Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitor therapy
Number of subjects: 20
Study 32205604 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula
Number of subjects: 1017
Study 32205788 — intervention group
Group type: EXPERIMENTAL
Intervention: Common Data Elements (CDEs) applied across studies
Number of subjects: 179
Study 32205788 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized codebooks and data collection protocols
Number of subjects: 179
Study 32205788 — intervention group
Group type: EXPERIMENTAL
Intervention: Research data repository for self-management of chronic conditions
Number of subjects: 179
Study 32206091 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior circulation ICAPs
Number of subjects: 202
Study 32206091 — intervention group
Group type: COMPARATOR
Intervention: Anterior circulation ICAPs
Number of subjects: 202
Study 32206091 — intervention group
Group type: EXPERIMENTAL
Intervention: Diffuse distribution ICAP feature
Number of subjects: 202
Study 32206312 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally competent social robots
Number of subjects: 45
Study 32206312 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 45
Study 32206334 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy (IPT) + usual care
Number of subjects: 50
Study 32206334 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 50
Study 32206659 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal instillation of bupivacaine
Number of subjects: 287
Study 32206659 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary recruitment maneuver with intraperitoneal bupivacaine
Number of subjects: 287
Study 32206659 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 287
Study 32206659 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 insufflation
Number of subjects: 287
Study 32206659 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of pulmonary recruitment maneuver and intraperitoneal bupivacaine
Number of subjects: 287
Study 32206660 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxaloacetate/vitamin C (2 capsules of 100 mg oxaloacetate/150 mg ascorbic acid)
Number of subjects: 48
Study 32206660 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2 capsules of rice flour)
Number of subjects: 48
Study 32206673 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Functional Mobilization (EFM) including immediate postoperative loading and ankle motion
Number of subjects: 135
Study 32206673 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (2 weeks of unloading in a plaster cast followed by 4 weeks of weightbearing in an orthosis)
Number of subjects: 135
Study 32206779 — intervention group
Group type: EXPERIMENTAL
Intervention: mTOR inhibition with sirolimus
Number of subjects: 88
Study 32206779 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-6 stimulation
Number of subjects: 88
Study 32206779 — intervention group
Group type: COMPARATOR
Intervention: mTORC1 signaling
Number of subjects: 88
Study 32206779 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline mTOR pathway activation
Number of subjects: 88
Study 32206973 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab therapy for 24 months
Number of subjects: 783
Study 32206976 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent scalp-sparing radiation (60 Gy in 30 fractions) with standard concurrent temozolomide (75 mg/m2) and tumor treatment fields (TTFields)
Number of subjects: 10
Study 32206991 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib
Number of subjects: 13
Study 32207049 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic sleeve gastrectomy (LSG)
Number of subjects: 23
Study 32207164 — intervention group
Group type: EXPERIMENTAL
Intervention: Imalumab (oxMIF inhibitor) at doses of 1 to 50 mg/kg IV every 2 weeks or 10 or 25 mg/kg IV weekly (1 cycle = 28 days)
Number of subjects: 50
Study 32208121 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory blood pressure monitoring (ABPM) performed at baseline in all patients.
Number of subjects: 1027
Study 32208121 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic adjustment or treatment switch after pathological ABPM.
Number of subjects: 1027
Study 32208121 — intervention group
Group type: EXPERIMENTAL
Intervention: Initiation of antihypertensive therapy after pathological ABPM.
Number of subjects: 1027
Study 32208831 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryptogenic ischemic stroke patients
Number of subjects: 60
Study 32208873 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecularly matched therapy
Number of subjects: 0
Study 32208873 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 32208953 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical assessment
Number of subjects: 0
Study 32208953 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphofluoroscopy
Number of subjects: 0
Study 32208957 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivosidenib (AG-120) monotherapy
Number of subjects: 21
Study 32209572 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib (single-agent)
Number of subjects: 0
Study 32209584 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB) surgery
Number of subjects: 19
Study 32209624 — intervention group
Group type: EXPERIMENTAL
Intervention: Current systemic or topical treatment for AD (at the discretion of the investigator)
Number of subjects: 1300
Study 32209628 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective sigmoidectomy
Number of subjects: 0
Study 32209661 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 32210181 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe OSA (AHI > 30 events/h)
Number of subjects: 128
Study 32210181 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate OSA (AHI > 10)
Number of subjects: 128
Study 32210181 — intervention group
Group type: COMPARATOR
Intervention: Matched controls (AHI < 5)
Number of subjects: 128
Study 32210181 — intervention group
Group type: COMPARATOR
Intervention: Controls (AHI < 5)
Number of subjects: 128
Study 32210458 — intervention group
Group type: EXPERIMENTAL
Intervention: TDF-containing regimen
Number of subjects: 106
Study 32210458 — intervention group
Group type: COMPARATOR
Intervention: Non-TDF-containing regimen
Number of subjects: 106
Study 32210458 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-treatment CD4+ count <350 cells/mm3
Number of subjects: 106
Study 32210527 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg intravitreal aflibercept (IVT-AFL) every 4 weeks (2q4)
Number of subjects: 378
Study 32210527 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg intravitreal aflibercept (IVT-AFL) every 8 weeks (2q8)
Number of subjects: 378
Study 32210527 — intervention group
Group type: COMPARATOR
Intervention: Macular laser photocoagulation (laser control group)
Number of subjects: 378
Study 32210527 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg intravitreal aflibercept (IVT-AFL)
Number of subjects: 378
Study 32210527 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 378
Study 32210548 — intervention group
Group type: EXPERIMENTAL
Intervention: VWF-N
Number of subjects: 984
Study 32210548 — intervention group
Group type: EXPERIMENTAL
Intervention: VWF-A
Number of subjects: 984
Study 32210639 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible extended regimen of ethinylestradiol/drospirenone (EE/DRSP)
Number of subjects: 212
Study 32210639 — intervention group
Group type: COMPARATOR
Intervention: Cyclic regimen of ethinylestradiol/drospirenone (EE/DRSP)
Number of subjects: 212
Study 32210897 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight self-monitoring (Intervention Group)
Number of subjects: 54
Study 32210897 — intervention group
Group type: COMPARATOR
Intervention: No weight self-monitoring (Control Group)
Number of subjects: 54
Study 32210906 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilvadipine (dihydropyridine calcium channel blocker)
Number of subjects: 0
Study 32210906 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 32211336 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium carbonate 300 mg given 2-3 times daily, adjusted to target serum concentration (0.6 to 1.0 mmol/L); Tretinoin 22.5 or 45 mg/m²
Number of subjects: 9
Study 32211554 — intervention group
Group type: EXPERIMENTAL
Intervention: SCHOOL IN ACTION program
Number of subjects: 0
Study 32211756 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g of ceftolozane/tazobactam administered q8h
Number of subjects: 26
Study 32212002 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (RTX) treatment
Number of subjects: 0
Study 32212002 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetuin-A and TBG levels
Number of subjects: 0
Study 32212061 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 0
Study 32212061 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 0
Study 32212061 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor and Clopidogrel
Number of subjects: 0
Study 32212069 — intervention group
Group type: EXPERIMENTAL
Intervention: Social support
Number of subjects: 83
Study 32212069 — intervention group
Group type: COMPARATOR
Intervention: Food insecurity (FI)
Number of subjects: 83
Study 32212069 — intervention group
Group type: COMPARATOR
Intervention: Health-related quality of life (HRQoL)
Number of subjects: 83
Study 32212104 — intervention group
Group type: EXPERIMENTAL
Intervention: Crisaborole ointment, 2%, applied twice daily for 28 days
Number of subjects: 137
Study 32212368 — intervention group
Group type: EXPERIMENTAL
Intervention: A1C ≥ 8% and LVEF < 40%
Number of subjects: 4091
Study 32212368 — intervention group
Group type: COMPARATOR
Intervention: A1C < 7% and LVEF ≥ 50%
Number of subjects: 4091
Study 32212368 — intervention group
Group type: EXPERIMENTAL
Intervention: Per 1% higher A1C
Number of subjects: 4091
Study 32212368 — intervention group
Group type: EXPERIMENTAL
Intervention: Per 10% lower in LVEF
Number of subjects: 4091
Study 32212910 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher exercise capacity (measured in METs)
Number of subjects: 270
Study 32212910 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported exercise
Number of subjects: 270
Study 32212933 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioelectrical impedance vector analysis-derived phase angle
Number of subjects: 0
Study 32212944 — intervention group
Group type: EXPERIMENTAL
Intervention: octanorm (cutaquig)
Number of subjects: 0
Study 32213027 — intervention group
Group type: EXPERIMENTAL
Intervention: Probe-based confocal laser endomicroscopy (pCLE)
Number of subjects: 67
Study 32213027 — intervention group
Group type: COMPARATOR
Intervention: Standard biopsies
Number of subjects: 67
Study 32213183 — intervention group
Group type: EXPERIMENTAL
Intervention: Waist circumference (WC) increase of 1 SD in men
Number of subjects: 10251
Study 32213183 — intervention group
Group type: EXPERIMENTAL
Intervention: Waist circumference (WC) increase of 1 SD in women
Number of subjects: 10251
Study 32213183 — intervention group
Group type: EXPERIMENTAL
Intervention: Fourth quartile of WC in men
Number of subjects: 10251
Study 32213183 — intervention group
Group type: EXPERIMENTAL
Intervention: Fourth quartile of WC in women
Number of subjects: 10251
Study 32213338 — intervention group
Group type: EXPERIMENTAL
Intervention: EORTC QLQ-LC29 questionnaire
Number of subjects: 523
Study 32213338 — intervention group
Group type: EXPERIMENTAL
Intervention: EORTC QLQ-C30 questionnaire
Number of subjects: 523
Study 32213344 — intervention group
Group type: EXPERIMENTAL
Intervention: Melflufen plus dexamethasone (40 mg melflufen, 40 mg dexamethasone weekly)
Number of subjects: 81
Study 32213344 — intervention group
Group type: COMPARATOR
Intervention: Single-agent melflufen
Number of subjects: 81
Study 32213344 — intervention group
Group type: EXPERIMENTAL
Intervention: Melflufen plus dexamethasone
Number of subjects: 81
Study 32213479 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth devices (AnaMed Original Equipment Manufacturer device and Air Next mobile spirometry device) used for 90 days alongside standard care
Number of subjects: 27
Study 32213479 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth devices
Number of subjects: 27
Study 32213649 — intervention group
Group type: EXPERIMENTAL
Intervention: setmelanotide
Number of subjects: 1
Study 32213649 — intervention group
Group type: COMPARATOR
Intervention: metreleptin
Number of subjects: 1
Study 32213860 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-Care for Older PErsons (SCOPE) program
Number of subjects: 378
Study 32214793 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.19 mg Fluocinolone Acetonide intravitreal implant
Number of subjects: 22
Study 32215273 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentle Jogger (JD) used for 30 minutes, 3 times per day for 7 days
Number of subjects: 22
Study 32215826 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled ovarian stimulation (COS) with gonadotropins
Number of subjects: 2901
Study 32216697 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic Keyhole Repair
Number of subjects: 0
Study 32216697 — intervention group
Group type: COMPARATOR
Intervention: Sugarbaker Repair
Number of subjects: 0
Study 32216750 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouth culture
Number of subjects: 200
Study 32216750 — intervention group
Group type: COMPARATOR
Intervention: Throat culture (reference standard)
Number of subjects: 200
Study 32216919 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline Anemia
Number of subjects: 0
Study 32216919 — intervention group
Group type: COMPARATOR
Intervention: Control group (no baseline anemia)
Number of subjects: 0
Study 32216975 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR)
Number of subjects: 2130
Study 32217004 — intervention group
Group type: EXPERIMENTAL
Intervention: Supported self-management (SMS) program
Number of subjects: 15
Study 32217063 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated PE
Number of subjects: 510
Study 32217226 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar Disorder (BD)
Number of subjects: 739
Study 32217652 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 32217877 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-reported outcome measures (PROMs) including the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 and the Outcomes and Experiences Questionnaire
Number of subjects: 0
Study 32218061 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertical Jump (VJ) on a force plate
Number of subjects: 20
Study 32218346 — intervention group
Group type: EXPERIMENTAL
Intervention: Resectable group (Res)
Number of subjects: 814
Study 32218346 — intervention group
Group type: EXPERIMENTAL
Intervention: Locally advanced group (LA)
Number of subjects: 814
Study 32218346 — intervention group
Group type: EXPERIMENTAL
Intervention: Metastatic group (Met)
Number of subjects: 814
Study 32218581 — intervention group
Group type: EXPERIMENTAL
Intervention: pOpmètre® device
Number of subjects: 50
Study 32218581 — intervention group
Group type: COMPARATOR
Intervention: SphygmoCor® device
Number of subjects: 50
Study 32218581 — intervention group
Group type: EXPERIMENTAL
Intervention: pOpmètre® device with algorithm correction
Number of subjects: 50
Study 32218749 — intervention group
Group type: EXPERIMENTAL
Intervention: iTBS
Number of subjects: 60
Study 32218749 — intervention group
Group type: COMPARATOR
Intervention: sham iTBS
Number of subjects: 60
Study 32218807 — intervention group
Group type: EXPERIMENTAL
Intervention: Apatinib (first line, second line, and third or higher line therapy)
Number of subjects: 337
Study 32218807 — intervention group
Group type: EXPERIMENTAL
Intervention: Apatinib (low-dose 250 mg, mid-dose 425-500 mg, high-dose 675-850 mg)
Number of subjects: 337
Study 32219330 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin treatment (MET)
Number of subjects: 249
Study 32219330 — intervention group
Group type: COMPARATOR
Intervention: Nonpharmacological treatment (NPT)
Number of subjects: 249
Study 32219388 — intervention group
Group type: EXPERIMENTAL
Intervention: Phased radiofrequency ablation
Number of subjects: 1054
Study 32219418 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite risk score
Number of subjects: 302
Study 32219418 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-served food portions
Number of subjects: 302
Study 32219418 — intervention group
Group type: EXPERIMENTAL
Intervention: Eating rate
Number of subjects: 302
Study 32219418 — intervention group
Group type: EXPERIMENTAL
Intervention: Lunch intakes
Number of subjects: 302
Study 32219418 — intervention group
Group type: EXPERIMENTAL
Intervention: Eating behaviors moderation
Number of subjects: 302
Study 32219421 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal fasting glucose increase (1-mmol/L)
Number of subjects: 305
Study 32219421 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal 2-h OGTT glucose increase (1-mmol/L)
Number of subjects: 305
Study 32219431 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocodone-acetaminophen prescribed (median 12 pills)
Number of subjects: 260
Study 32219675 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide 1.5 mg
Number of subjects: 264
Study 32219675 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide 0.75 mg
Number of subjects: 264